An observational study in Ischemic Cerebrovascular Disease and Blood Pressure Variability, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-14.
Sponsored by Xuanwu Hospital, Beijing · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing — 30 open to participants now, 31 under way, 2 of them phase 3. Ischemic Stroke · Xuanwu Hospital, Beijing.
Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 13th largest by planned enrollment of the 24 observational ones that give a count, is one of 4 that started in 2022, is one of 24 observational ones, reaches primary completion later than 12 of the 30 other live ones, and was the 13th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →30 of the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 3 · Phase 4 6
First in 2012; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is close to the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 325 across the 28 interventional studies, 350 across the 24 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
13 of the studies in Ischemic Stroke by Xuanwu Hospital, Beijing that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT07419997Xuanwu Hospital, BeijingA Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke | 2026-12-29 |
| NCT07519044Xuanwu Hospital, BeijingSafety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion | 2027-01-31 |
| NCT05232240Xuanwu Hospital, BeijingBlood Pressure Variability in Non-hypertensive Patients With Ischemic Cerebrovascular Disease | 2027-02 |
| NCT07882030Xuanwu Hospital, BeijingEarly Administration of Angong Niuhuang Pill for Disabling Acute Ischemic Stroke (EAGER Trial) | 2027-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-center prospective cohort of patients with ischemic cerebrovascular disease (ICVD) who have not met the diagnostic criteria for hypertension. Ambulatory 24-hour blood pressure monitoring (ABPM) will be performed at baseline and one year after the enrollment. The primary purpose of the study is to delineate the relationship of blood pressure variability (BPV) with the risk of composite vascular events in non-hypertensive patients with ICVD. The factors related to BPV, as well as the potential modulators of the associations between BPV and vascular risk, will be further explored among these patients.
Hypertension is one of the most important risk factors of ischemic cerebrovascular disease (ICVD), while various blood pressure variability (BPV) indices are immerging as novel prognostic indicators independent of the blood pressure level. However, the BPV profiles without hypertension have not been specifically observed. Considering the great importance of blood pressure management in ICVD, more research is needed to clarify whether and how BPV will increase the vascular risk in non-hypertensive patients with ICVD. This prospective cohort study will be helpful to invoke an early management of blood pressure in patients with ICVD before the clinical establishment of hypertension.
All eligible non-hypertensive patients hospitalized for ICVD will be consecutively enrolled in this cohort. Blood pressure measurements are obtained with ambulatory 24-hour blood pressure monitoring (ABPM) every 20 minutes during day-time (6:00-22:00) and every 30 minutes during night-time (22:00-6:00) at baseline and one year after the enrollment. The clinical, imaging and laboratory information will be collected at baseline. During an estimated 3-year follow-up, the vessel-related diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports and investigators' regular telephone visits.
The patients are diagnosed as ischemic cerebrovascular disease (ICVD) and less than 90 days after the onset of ischemic stroke or transient ischemic attack. The patients have no definite diagnosis of hypertension, and are not under anti-hypertension treatment. The blood pressure measured 5\~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥ 2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients are diagnosed as ischemic cerebrovascular disease (ICVD) and less than 90 days after the onset of ischemic stroke or transient ischemic attack. The patients have no definite diagnosis of hypertension, and are not under anti-hypertension treatment. The blood pressure measured 5\~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥ 2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).
Diagnostic Test: blood pressure variability measured by ambulatory 24-hour blood pressure monitoring
The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.
3-year risk of Major Adverse Cardiovascular Event
the time of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina
Time frame: 3 years
90-day Functional Outcome
percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled
Time frame: 90 days
1-year rate of Major Adverse Cardiovascular Event
the rate of cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina
Time frame: 1 year
1-year rate of Ischemic Stroke
the rate of fatal and nonfatal ischemic stroke
Time frame: 1 year
1-year rate of Acute Coronary Syndrome
the rate of first documented fatal and nonfatal myocardial infarction and unstable angina
Time frame: 1 year
1-year rate of Cardiovascular Mortality
the rate of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death
Time frame: 1 year
3-year risk of Ischemic Stroke
the time of first documented fatal or nonfatal ischemic stroke
Time frame: 3 years
3-year risk of Acute Coronary Syndrome
the time of first documented fatal or nonfatal myocardial infarction or unstable angina
Time frame: 3 years
3-year risk of Cardiovascular Mortality
the time of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death
Time frame: 3 years
Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 60 months is close to that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.